B Cell Lymphoma
From the Journals
Radiation bridging with axi-cel appears safe in DLBCL
At final follow-up, in a case series of 12 patients with relapsed/refractory DLBCL, the best objective response rate was 81.8%, with complete...
From the Journals
Polatuzumab vedotin combo shows promise in DLBCL
Polatuzumab vedotin plus rituximab or obinutuzumab, in addition to cyclophosphamide, doxorubicin, and prednisone, showed manageable safety and...
From the Journals
Influenza vaccination status in DLBCL poorly documented
Routine outpatient vaccination screening and strategies for sharing and linking patient vaccination status could improve vaccination documentation...
Conference Coverage
Rituximab and vemurafenib could challenge frontline chemotherapy for HCL
AMSTERDAM – The investigators called for randomized testing to compare the combination to standard chemotherapy in the frontline setting for hairy...
Conference Coverage
Cell count ratios appear to predict thromboembolism in lymphoma
AMSTERDAM – The findings mean clinicians can look to complete blood count for answers on thromboembolism risk.
From the Journals
Hedgehog signaling offers prognostic, therapeutic potential in CLL
Hedgehog signaling was associated with expression of GLI1, which could be a future therapeutic target.
From the Journals
BET inhibitors may target oncogene in ABC-like DLBCL
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
5F9 plus rituximab take a bite out of drug-resistant NHL
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
Conference Coverage
Obinutuzumab provides strong early responses in untreated MCL
AMSTERDAM – A minimal residual disease rate as high as 85% is “unprecedented” in this population of patients, the lead investigator of the LYMA-...
Conference Coverage
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCL
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.